Dong-A ST Co., Ltd. (KRX:170900)
South Korea
· Delayed Price · Currency is KRW 45,000
+150 (0.33%)
Apr 18, 2025, 3:30 PM KST
Dong-A ST Revenue
In the year 2024, Dong-A ST had annual revenue of 697.87B KRW with 5.10% growth. Dong-A ST had revenue of 178.62B in the quarter ending December 31, 2024, a decrease of -1.35%.
Revenue
697.87B
Revenue Growth
+5.10%
P/S Ratio
0.59
Revenue / Employee
413.67M
Employees
1,687
Market Cap
412.34B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 697.87B | 33.89B | 5.10% |
| Dec 31, 2023 | 663.98B | 28.59B | 4.50% |
| Dec 31, 2022 | 635.39B | 42.16B | 7.11% |
| Dec 31, 2021 | 593.23B | 6.50B | 1.11% |
| Dec 31, 2020 | 586.73B | -25.58B | -4.18% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,547.32B |
| Celltrion | 3,557.30B |
| ALTEOGEN | 102.85B |
| Yuhan | 2,067.79B |
| SK Biopharmaceuticals | 547.60B |
| HLB Co., Ltd. | 68.13B |
| LigaChem Biosciences | 125.90B |
| Peptron | 3.15B |
Dong-A ST News
- 4 months ago - Dong-A ST Secures European Approval for Stelara Biosimilar IMULDOSA - Financial Post
- 6 months ago - US FDA Approves Dong-A ST’s IMULDOSA™ (ustekinumab-srlf), a Biosimilar to STELARA® - Financial Post
- 6 months ago - US FDA Approves Dong-A ST's IMULDOSA™ (ustekinumab-srlf), a Biosimilar to STELARA® - Benzinga